News
NPCE
15.92
-1.67%
-0.27
Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)
TipRanks · 3d ago
NeuroPace Is Maintained at Overweight by JP Morgan
Dow Jones · 5d ago
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $20
Benzinga · 5d ago
NeuroPace price target raised to $20 from $18 at JPMorgan
TipRanks · 5d ago
UBS Keeps Their Buy Rating on NeuroPace (NPCE)
TipRanks · 6d ago
Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE) and Evaxion Biotech (EVAX)
TipRanks · 12/08 13:50
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
TipRanks · 12/08 13:16
NeuroPace Presents Preliminary 18-Month Safety And Effectiveness Results From Ongoing NAUTILUS1 Trial Evaluating RNS System As Adjunctive Therapy For Treatment Of ASM Resistant IGE With GTC Seizures, At AES Meeting
Benzinga · 12/08 13:10
NEUROPACE: REMAINS ON TRACK TO SUBMIT NAUTILUS PMA SUPPLEMENT TO FDA FOR IGE INDICATION EXPANSION BY YEAR-END
Reuters · 12/08 13:05
NeuroPace Reports Positive 18-Month Results from NAUTILUS Trial for Drug-Resistant Epilepsy
Reuters · 12/08 13:01
Weekly Report: what happened at NPCE last week (1201-1205)?
Weekly Report · 12/08 09:19
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
Barchart · 12/08 07:00
Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025
Reuters · 12/02 13:02
Weekly Report: what happened at NPCE last week (1124-1128)?
Weekly Report · 12/01 09:18
BUZZ-U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
Reuters · 11/24 18:52
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Reuters · 11/24 15:52
BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials
Reuters · 11/24 14:19
NeuroPace (NPCE) Gets a Buy from Lake Street
TipRanks · 11/24 13:55
BUZZ-NeuroPace jumps as Medicare boosts pay for epilepsy device procedures
Reuters · 11/24 13:45
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.